ATE419363T1 - Pharmazeitische impfstoffe gegen hiv - Google Patents

Pharmazeitische impfstoffe gegen hiv

Info

Publication number: ATE419363T1
Authority: AT; Austria
Prior art keywords: gene product; hiv; pol; gag; nef
Prior art date: 2003-09-24

Application number

AT04768582T

Other languages

English (en)

Inventor

Joerg Schneider

Original Assignee

Oxxon Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-24

Filing date

2004-09-23

Publication date

2009-01-15

2003-09-24 Priority claimed from GB0322402A external-priority patent/GB0322402D0/en

2003-09-26 Priority claimed from GB0322637A external-priority patent/GB0322637D0/en

2004-09-23 Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419363T1 publication Critical patent/ATE419363T1/de

Links

229960005486 vaccine Drugs 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
101710177291 Gag polyprotein Proteins 0.000 abstract 1
108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
108010089520 pol Gene Products Proteins 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
239000013603 viral vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Immunology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT04768582T 2003-09-24 2004-09-23 Pharmazeitische impfstoffe gegen hiv ATE419363T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0322402A GB0322402D0 (en)	2003-09-24	2003-09-24	HIV pharmaccines
GB0322637A GB0322637D0 (en)	2003-09-26	2003-09-26	HIV pharmaccines
GB0325011A GB2406336A (en)	2003-09-24	2003-10-27	HIV Pharmaccines

Publications (1)

Publication Number	Publication Date
ATE419363T1 true ATE419363T1 (de)	2009-01-15

Family

ID=29738123

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04768582T ATE419363T1 (de)	2003-09-24	2004-09-23	Pharmazeitische impfstoffe gegen hiv

Country Status (3)

Country	Link
AT (1)	ATE419363T1 (de)
DE (1)	DE602004018817D1 (de)
GB (1)	GB2406336A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012201827B2 (en) *	2005-05-12	2014-09-04	Glaxo Group Limited	Vaccine composition
AU2006245920A1 (en) *	2005-05-12	2006-11-16	Glaxo Group Limited	Vaccine composition
JP7693813B2 (ja) *	2021-01-14	2025-06-17	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖワクチン及び使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783939B2 (en) *	2000-07-07	2004-08-31	Alphavax, Inc.	Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
EP2302059A1 (de) *	2000-08-14	2011-03-30	The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services	Modifikationen der Env-, Gag- und Pol-Protein des Hiv-Virus erhöhen die Immunogenwirkung genetischer Impfstoffe
WO2002022080A2 (en) *	2000-09-15	2002-03-21	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CN100392085C (zh) *	2001-09-20	2008-06-04	葛兰素集团有限公司	疫苗

2003
- 2003-10-27 GB GB0325011A patent/GB2406336A/en not_active Withdrawn
2004
- 2004-09-23 DE DE602004018817T patent/DE602004018817D1/de not_active Expired - Fee Related
- 2004-09-23 AT AT04768582T patent/ATE419363T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE602004018817D1 (de)	2009-02-12
GB0325011D0 (en)	2003-12-03
GB2406336A (en)	2005-03-30

Similar Documents

Publication	Publication Date	Title
AU2006283101B2 (en)	2013-03-07	Polyvalent vaccine
Rosati et al.	2005	DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge
Paris et al.	2010	Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
Otten et al.	2005	Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins
CN1325512C (zh)	2007-07-11	Hiv调节/辅助蛋白的融合蛋白
Bansal et al.	2008	Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
CY1107818T1 (el)	2013-06-19	Hiv-1 tat, ή παραγωγα αυτου για προφυλακτικο και θεραπευτικο εμβολιασμο
Karpenko et al.	2014	Novel approaches in polyepitope T-cell vaccine development against HIV-1
US8916174B2 (en)	2014-12-23	HIV DNA vaccine regulated by a caev-derived promoter
ES2282041A1 (es)	2007-10-01	Mejoras introducidas en el objeto de la patente principal n es200501841 para "vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida".
von Gegerfelt et al.	2007	Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization
AR041764A1 (es)	2005-05-26	Vacuna basada en polinucleotidos y proteinas derivados del vih
ATE419363T1 (de)	2009-01-15	Pharmazeitische impfstoffe gegen hiv
US8765140B2 (en)	2014-07-01	DNA vaccine compositions with HIV/SIV gene modifications
US12194088B2 (en)	2025-01-14	Compositions and methods for promoting immune responses to human immunodeficiency virus
US20090169503A1 (en)	2009-07-02	Dna-based vaccination of retroviral-infected individuals undergoing treatment
Hanke et al.	2016	Vector delivery-dependant effect of human tissue plasminogen activator signal peptide on vaccine induction of T cells
MX2021011439A (es)	2023-03-21	Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente.
CA2325345A1 (en)	1999-10-14	Medicaments for inducing cytotoxic t-cells
JP2006506094A (ja)	2006-02-23	Ｒｒｅおよびｃｔｅを含む遺伝的構築物および組成物ならびにそれらの使用
Sommerfelt et al.	2004	Novel peptide-based HIV-1 immunotherapy
Lemiale et al.	2001	Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches
Khan et al.	2023	TGF-β1 in Aplysia: Role in Long-Term Changes in the Excitability of Sensory Neurons and Distribution of TβR-II-Like Immunoreactivity
RU2335540C1 (ru)	2008-10-10	ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-nef(A)-hum
FR2825280B1 (fr)	2005-04-15	Vaccination contre le virus de l'immunodeficience feline

Legal Events

Date	Code	Title	Description
2009-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties